1. Introduction {#sec1-antibiotics-09-00261}
===============

*Klebsiella pneumoniae* is a Gram-negative, encapsulated, non-motile bacterium, being one of the six most important healthcare-associated pathogens (ESKAPE) which often exhibit multidrug resistance and/or are highly virulent, thus causing major healthcare concerns. The virulence of *K. pneumoniae* is determined by numerous factors including the polysaccharide capsule that allows the bacterium to evade phagocytosis by the host \[[@B1-antibiotics-09-00261]\], type 1 and 3 fimbriae responsible for bacterial cell adhesion \[[@B1-antibiotics-09-00261]\] and various siderophores used for iron uptake \[[@B2-antibiotics-09-00261]\]. Several hypervirulent types of *K. pneumoniae* carry genes associated with life-threating invasive diseases \[[@B3-antibiotics-09-00261]\].

The treating of infections associated with this bacterium is also complicated due to the emergence of carbapenem-resistant strains revealed in the mid-2000 s. This infection has spread around the world, and it represents a serious problem due to its high mortality rate, which can sometimes exceed 50% \[[@B4-antibiotics-09-00261]\]. Making matters worse, recently an isolate was reported that included both a hypervirulence and a carbapenemase-encoding plasmid \[[@B5-antibiotics-09-00261]\]. The optimal treatment of infections due to the carbapenemase-producing *K. pneumoniae* remains unknown \[[@B6-antibiotics-09-00261]\]. Colistin is one of the antibiotics of last resort for the treatment of such infections, but *K. pneumoniae* isolates resistant to this drug have already been reported \[[@B7-antibiotics-09-00261]\], and more than 10% of the isolates are estimated to be colistin-resistant in Greece \[[@B8-antibiotics-09-00261]\]. Five such isolates are described in the present study.

The development of novel antimicrobial drugs and therapies is hindered by the fact that many resistance mechanisms have not yet been revealed, although the increasing availability of whole-genome sequencing (WGS) greatly facilitates such investigations. Thus, additional data linking antimicrobial resistance determined by traditional methods with genomic traits are required. A number of studies comparing *K. pneumoniae* resistomes determined by traditional and in silico methods were conducted \[[@B4-antibiotics-09-00261],[@B9-antibiotics-09-00261],[@B10-antibiotics-09-00261],[@B11-antibiotics-09-00261],[@B12-antibiotics-09-00261]\], some of which were based on long-read WGS using the Oxford Nanopore MinION sequencing system \[[@B9-antibiotics-09-00261],[@B10-antibiotics-09-00261]\]. However, such a comparison would be much more useful if supplemented by broad epidemiological surveillance data, including the implementation of various molecular typing schemes, and by a thorough investigation of the associated virulence factors and plasmid resistance determinants.

In this paper, we provide the comprehensive data for 36 clinical *K. pneumoniae* isolates belonging to various sequence types (ST), including two novel ones not described before. Among these isolates, 32 were multidrug-resistant (MDR) according to the commonly used definition \[[@B13-antibiotics-09-00261]\]. We provide the results of isolate molecular typing using several schemes (MLST, capsular and oligosaccharide typing).

The MLST scheme for *K. pneumoniae* developed in 2005 \[[@B14-antibiotics-09-00261]\] includes the determination of internal fragments for the following seven housekeeping genes: *gapA* (glyceraldehyde 3-phosphate dehydrogenase), *infB* (translation initiation factor 2), *mdh* (malate dehydrogenase), *pgi* (phosphoglucose isomerase), *phoE* (phosphorine E), *rpoB* (beta-subunit of RNA polymerase) and *tonB* (periplasmic energy transducer), and a comparison of their allelic profiles with the ones from public databases \[[@B15-antibiotics-09-00261]\]. Currently, more than 4000 sequence type profiles for *K. pneumoniae* are contained in the Institut Pasteur MLST system \[[@B15-antibiotics-09-00261]\].

Additional isolate typing schemes for *K. pneumoniae* included the ones based on capsular (K, or KL) loci and oligosaccharide (O) loci. The current versions of the corresponding databases contain about 100 KL-type profiles and 12 O-profiles \[[@B16-antibiotics-09-00261]\]. KL1--KL77 correspond to the loci associated with each of the 77 serologically defined K-type references, and KL101 and above are defined from the DNA sequence data on the basis of the gene content.

There are many other available typing schemes, for example, based on sequence properties \[[@B17-antibiotics-09-00261]\], but in this study we used a combined approach including three molecular-based schemes.

The data also comprises antimicrobial resistance information, including plasmid determination, virulence genes' presence and several typing schemes. The resistance/susceptibility data were acquired by both traditional methods and bioinformatics-based methods for the bacterial whole genomes obtained by second and third generation (long-read) sequencing.

2. Results {#sec2-antibiotics-09-00261}
==========

2.1. Typing and Classification {#sec2dot1-antibiotics-09-00261}
------------------------------

In [Table 1](#antibiotics-09-00261-t001){ref-type="table"}, the results of typing our isolates using the three schemes described above are presented. The isolates belong to 16 different sequence types, with ST395 being the most abundant (seven isolates). In addition, there are 18 different KL-types and 9 O-types. Four isolates belong to the KL2 type, which is usually considered to be associated with high virulence \[[@B18-antibiotics-09-00261]\]. The most frequent O-type was O2v2 (11 isolates in total).

Three isolates (P-45, P-212 and P-259) possessed novel combinations of MLST-gene alleles, i.e., a new sequence type (ST), between which P-212 and P-259 had the same ST. The last two samples were taken from the same patient, but from different sites and in different times to ensure the presence of a novel ST. We have submitted these isolates to the Institut Pasteur MLST system \[[@B15-antibiotics-09-00261]\], and new MLST profiles were created for them: ST4060 for P-45 and ST4061 for the two other isolates. The allelic profiles of these new sequence types are presented in [Table 2](#antibiotics-09-00261-t002){ref-type="table"}.

In order to obtain additional information regarding bacteria similarity, a maximum likelihood tree was built based on the core genome of 36 isolates containing 3888 genes. The tree is presented below in [Figure 1](#antibiotics-09-00261-f001){ref-type="fig"}.

It is worth noting that the KL-type provides additional classification narrowing in comparison with the sequence type alone. For example, P-183 forms a standalone clade since it possesses the KL-type (KL23) different from its neighbors' type (KL24), although they share the same ST (ST11). Thus, such a hybrid typing scheme could be applied for a precise distinguishing of the isolates in clinical settings, which is an important task in epidemiological surveillance and infection prevention.

2.2. Antibiotic Resistance Determination {#sec2dot2-antibiotics-09-00261}
----------------------------------------

We have tested the isolates for antimicrobial drug resistance both by empirical (disc diffusion) and theoretical (searching for known acquired resistance genes in genomic sequences) methods. Although the empirical methods are more reliable, they undoubtedly require more time and resources. When the time is a critical factor, e.g., for patients with a severe unidentified bacterial infection, a quick bioinformatics scan for resistance based on a whole-genome sequence may become a promising option for future studies using third generation sequencers like MinION. However, currently, this technology cannot be readily implemented in routine clinical diagnostics since it allows only detecting the presence of some gene, but cannot reveal its expression or activation state.

Thus, in order to facilitate the development of such novel point-of-care resistance determination systems, a comprehensive comparison of empirical and theoretical susceptibility determination is required. We have performed such a comparison for all 36 *K. pneumoniae* isolates. The data obtained are summarized in [Figure 2](#antibiotics-09-00261-f002){ref-type="fig"}.

Phenotype studies have shown that 32 of the 36 isolates were MDR. Three isolates (P-28, P-29, and P-237) were resistant to 12 antimicrobial drugs that have been tested for all the isolates. Additional studies have shown that P-28, P-29 and P-237 were resistant to many other drugs, including commercially available *Klebsiella* bacteriophages, and were susceptible only to moxifloxacin (P-29, partially) and nalidixic acid (P-237, partially). P-28 was resistant to all antimicrobials from the extended panel.

Five isolates, including P-28, P-29 and P-237 mentioned above, were colistin-resistant, which is rather rare for *K. pneumoniae* \[[@B7-antibiotics-09-00261]\], since colistin is one of the antibiotics of last resort for the treatment of carbapenem-resistant *K. pneumoniae* infections \[[@B7-antibiotics-09-00261]\]. Interestingly, all three isolates of ST377 (P-26, P-28, P-152) were MDR. According to the isolates' data available in the Institut Pasteur database \[[@B15-antibiotics-09-00261]\], this sequence type is rather rare (only eight fully sequenced isolates in the Pasteur database, and only one in Genbank), and is usually attributed to MDR or extensively drug-resistant (XDR) bacteria. Thus, it requires specific attention in future studies.

All isolates were ampicillin-resistant, which corresponds well with their possession of SHV-type beta-lactamase genes revealed by bioinformatics methods. These genes are known to be chromosome-encoded and provide ampicillin resistance for *K. pneumoniae* \[[@B19-antibiotics-09-00261]\]. Most of the isolates were also resistant to other beta-lactam antibiotics, and half of the isolates (18/36) were resistant to carbapenems. This fact complies with the presence of the beta-lactamase genes *bla*~CTX-M-15~ (21 isolates), *bla*~TEM-1B~ (20 isolates), *bla*~OXA-1~ and *bla*~OXA-48~ (15 and 12 isolates, respectively). In addition, 26 isolates were resistant to ciprofloxacin, and this resistance is reflected in the presence of the *aac(6′)-lb-cr* gene, which is known to provide fluoroquinolone resistance in *Enterobacteriaceae* \[[@B20-antibiotics-09-00261]\].

Despite the fact that the antimicrobial resistance phenotypes and genotypes correlated in general, some discrepancies were found. This is not surprising because the presence of a resistance gene in a genome cannot be considered as sole evidence for its expression and activity in the given isolate. In addition, colistin resistance genes were not revealed by bioinformatics methods. However, ColRNAI plasmids known to carry such genes \[[@B21-antibiotics-09-00261]\] were found (see below). Difficulties in accurately identifying colistin resistance in vitro may also be at play with this discrepancy.

2.3. Plasmids {#sec2dot3-antibiotics-09-00261}
-------------

Since plasmids play a key role in acquired antimicrobial drug resistance, it is important to reveal the plasmid sequences in the WGS data. This information will greatly facilitate the investigations of resistance mechanisms. We have performed an in silico search for plasmids in all genomic sequences of the isolates. In addition, sequencing with long reads usually provides necessary resolution to separate genomic and plasmid sequences during reads' assembly to contigs \[[@B22-antibiotics-09-00261]\], so we have also checked the plasmid presence in hybrid short--long reads' assemblies for the 14 selected isolates. The list of plasmids identified in the isolates is shown below in [Table 3](#antibiotics-09-00261-t003){ref-type="table"}.

The plasmid data correspond with the antimicrobial resistance data obtained by the traditional and in silico methods. For example, IncF-type plasmids revealed in most isolates are commonly reported worldwide to carry carbapenemase genes and quinolone resistance genes \[[@B23-antibiotics-09-00261]\], which were found in most isolates.

The ColRNAI plasmid carrying colistin resistance genes was revealed in three MDR (P-28, P-29 and P-152) isolates belonging to the ST377 sequence type. This plasmid was also found in hypervirulent P-108 and P-140, but their phenotypic resistance/sensitivity to colistin was not confirmed, as well as for P-152, since we have not performed the serial dilution approach to confirm their sensitivity. Nevertheless, the isolates having this plasmid require additional attention. At the same time, the other colistin-resistant isolates P-26 and P-200 had an IncH plasmid that is associated with the *mcr-1* and *mcr-3* plasmid-mediated colistin resistance genes in *E. coli* \[[@B23-antibiotics-09-00261],[@B24-antibiotics-09-00261]\]. However, *mcr* genes have not been revealed in P-26, P-28, P-29 or P-200, which suggests some different resistance mechanism. In P-237, the plasmid has not been revealed either. However, the long-read sequencing of the selected samples confirmed the possibility of the plasmid mechanism of antimicrobial resistance acquisition to other antibiotics in most isolates.

In general, although the long-read sequencing allowed to obtain the reliable whole-plasmid sequences, it did not provide additional information regarding plasmid typing. Deeper investigations of plasmid sequences and structure are required to get additional insights in resistance transfer mechanisms, but such studies lie beyond the scope of this manuscript.

2.4. Virulence Genes {#sec2dot4-antibiotics-09-00261}
--------------------

Besides the antibiotic resistance data, another important piece of information is the virulence of the investigated isolates that represents the degree of damage caused by a bacterium to its host. Although the bacteria of some sequence types, especially ST23, were considered to be hypervirulent \[[@B3-antibiotics-09-00261]\], it is not always possible to link the sequence type to the virulence characteristics which contribute to the pathogenicity of the bacteria. Thus, it would be useful to identify known virulence factor genes in the genomes of the isolates investigated by bioinformatics methods.

*K. pneumoniae* has many virulence factors, for example, lipopolysaccharide, fimbriae, outer membrane proteins and determinants of iron acquisition and nitrogen source utilization \[[@B25-antibiotics-09-00261]\].

Several panels of genes encoding the virulence factors were proposed. Usually, the genes specifying the K1 (*magA*) and K2 (*wzi*) serotypes, together with seven other virulence factors (*rmpA*, *entB*, *ybtS*, *kfu*, *iutA*, *mrkD*, *allS*) are considered important \[[@B18-antibiotics-09-00261],[@B26-antibiotics-09-00261]\]. The less studied factors associated with *K. pneumoniae* virulence include outer membrane proteins (porins) and the allantoin metabolism system \[[@B1-antibiotics-09-00261]\].

The complete list of detected virulence genes is shown in the [Supplementary Material's Table S1](#app1-antibiotics-09-00261){ref-type="app"}, and the presence of the main virulence factors given above is shown in [Figure 3](#antibiotics-09-00261-f003){ref-type="fig"}.

All isolates possessed *allS* (allantoinase gene) and *entB* (enterobactin), while *mrkD* (fimbriae, 28 isolates) and *ybtS* (yersiniabactin, 18 isolates) were rather common as well. In addition, most isolates (from 26 to 33 for different genes) contained other genes of the *mrk* cluster, which are involved in type 3 fimbriae formation \[[@B1-antibiotics-09-00261]\], suggesting that this virulence mechanism is likely to be important in the isolates under study. The *rmpA* (regulator of mucoid phenotype A) gene was rare and was revealed only in two isolates (P-108, P-140) belonging to the hypervirulent ST23 type. This high degree of virulence was also supported by the fact that only these two isolates possessed 6 of 7 virulence genes studied. Genes from the *kfu* cluster (iron uptake system) were revealed in four isolates, including two (P-212 and P-259) possessing the novel sequence type ST4061. The aerobactin transporter gene (*iutA*) was found in 10 isolates. A half of all isolates contained four or more virulence factors, suggesting that they could be dangerous in clinical settings, as they are also MDR, and require further investigations.

3. Discussion {#sec3-antibiotics-09-00261}
=============

To the best of our knowledge, this is the first detailed molecular epidemiology report based on second and third generation whole-genome sequencing for clinical isolates of *K. pneumoniae* in the Russian Federation. In this study two new MLST-based sequence types represented by one and two isolates, respectively, were revealed. Both sequence types were deposited to the MLST database of the Institut Pasteur (Paris, France) \[[@B15-antibiotics-09-00261]\] as ST4060 and ST4061, respectively. We plan to collect additional samples to investigate the frequency of these sequence types and possible ways for their transmission. Since 36 isolates belonged to 16 different sequence types and 18 different KL-types without a significant prevalence of any type or spreading across all clinical departments, the data obtained cannot prove that all or most of the isolates had a nosocomial origin. Although this study included taking samples from patients visiting the medical center from various regions of the Russian Federation, it obviously cannot be considered as being representative of the whole country due to the very limited sample population.

Our study has confirmed the negative tendency of carbapenemase-producing pathogens' spread in various Russian high-technological medical centers described recently \[[@B27-antibiotics-09-00261]\] and in earlier publications \[[@B28-antibiotics-09-00261],[@B29-antibiotics-09-00261]\]. We believe that such investigations performed by us and our colleagues will highlight the importance of carbapenemase-producing pathogen surveillance and stimulate similar studies in other medical centers from different parts of Russia. In our opinion, currently, such investigations are scarce and their value is underestimated, but the situation gradually changes for the better.

It is also interesting that no ST258 isolates were revealed, although this sequence type is rather common in Europe, North America and Australia \[[@B30-antibiotics-09-00261]\]. However, 12 members of the clonal group 258 \[[@B30-antibiotics-09-00261]\] including, among others, ST11 and ST395 were found.

Thirty-two of 36 (89%) isolates expressed an MDR phenotype, 18 of them (50%) were resistant to carbapenems, and 5 to colistin (14%), while 3 were resistant to the whole panel of 12 antibiotics belonging to various classes. The in silico screening for the *mcr* genes in colistin-resistant isolates did not reveal any results, but the P-29 isolate carried a C-\>A mutation in position 29 of the *mgrB* gene, leading to a C39F amino acid substitution, which, in turn, could lead to function deactivation according to the PROVEAN server (<http://provean.jcvi.org/index.php>). Other isolates exhibited a wild-type *mgrB*, so the mechanisms of their resistance remain to be elucidated. This partially complies with the results obtained in recent colistin resistance investigations of *K. pneumoniae* from Greece \[[@B31-antibiotics-09-00261]\]. In addition, two isolates were hypervirulent that was confirmed by the presence of six important virulence factors in their genomes and their belonging to the ST23 sequence type. All three isolates attributed to the rarely revealed ST377 were MDR, including the one resistant to the extended panel, so this sequence type should be extensively studied in the future.

In most cases, there was a good compliance between the phenotypic and genotypic antibiotic resistance, but some discrepancies were revealed, in particular, for colistin, which suggests a possible resistance mechanism based on the chromosomal gene inactivation in such cases.

Long-read sequencing on MinION (Oxford Nanopore Technologies, Oxford, UK) allowed to greatly improve the assembly of 14 *K. pneumoniae* genomes (down to one contig for each genome), including the distinguishing of the plasmid sequences. The data obtained will facilitate future studies of antimicrobial resistance mechanisms in *Enterobacteria*.

In general, the prevalence of antibiotic resistance in the isolates with the hypermucoviscosity phenotype (hvKP, highly virulent) is rare compared with the high prevalence of antibiotic-resistant isolates \[[@B1-antibiotics-09-00261],[@B32-antibiotics-09-00261]\]. However, with the global dissemination of mobile genetic elements harboring various antibiotic resistance genes, including the *K. pneumoniae* carbapenemase (KPC), New Delhi metallo-beta-lactamase (NDM) and oxacillinases-48 (OXA-48) types of carbapenemases, antibiotic-resistant hvKP isolates have begun to emerge in recent years \[[@B32-antibiotics-09-00261]\]. In our study, we have determined two highly virulent isolates belonging to ST23. Although they had an MDR phenotype, their resistance, on average, was lower than for the less virulent isolates. In addition, the presence of five virulence factors in the highly resistant P-152 isolate belonging to ST377 need further investigation due to the possible emergence of a novel dangerous source of infection.

4. Materials and Methods {#sec4-antibiotics-09-00261}
========================

4.1. DNA Isolation, Sequencing and Genome Assembly {#sec4dot1-antibiotics-09-00261}
--------------------------------------------------

Thirty-six patient samples were obtained from 34 patients (21 males and 13 females) in various sources and clinical departments (see [Table 1](#antibiotics-09-00261-t001){ref-type="table"}) of a multipurpose medical center in Moscow, Russia, during the period 2017--2018. Patients' ages ranged from 24 to 98 with a median equal to 60 years. At the first step, 32 isolates resistant to at least 3 antimicrobial agents, as defined by the phenotype, were randomly selected from the set of available isolates. Then four additional isolates (P-6, P-15, P-45 and P-190) that have caused severe infections were included, even though they did not exhibit an MDR phenotype, in order to better investigate these cases and to exclude possible determination errors. The genomic DNA was isolated with a DNeasy Blood and Tissue kit (Qiagen, Hilden, Germany) and used for the paired-end library preparation with a Nextera^™^ DNA Sample Prep Kit (Illumina^®^, San Diego, CA, USA), and the WGS of all 36 isolates was performed on Illumina^®^ Hiseq or MiSeq platforms.

The WGS was also performed using the Oxford Nanopore MinION sequencing system (Oxford Nanopore Technologies, Oxford, UK). DNA was used to prepare the MinION library with the Rapid Barcoding Sequencing kit SQK-RBK004 (Oxford Nanopore Technologies, Oxford, UK). The amount of initial DNA used for the barcoding kit was 400 ng for each sample. All mixing steps for the DNA samples were performed by gently flicking the microfuge tube instead of pipetting. All libraries were prepared according to the manufacturer's protocols. The final library was sequenced on an R9 SpotON flow cell. The standard 24 h sequencing protocol was initiated using the MinKNOW software (Oxford Nanopore Technologies, Oxford, UK). Fourteen of 36 isolates considered interesting according to various criteria were sequenced.

Base calling of the raw MinION data was performed with the Guppy Basecalling Software version 2.3.1 (Oxford Nanopore Technologies, Oxford, UK). Demultiplexing was made using Deepbinner version 0.2.0 \[[@B33-antibiotics-09-00261]\]. Assemblies were obtained using SPAdes version 3.10 \[[@B34-antibiotics-09-00261]\] (Illumina sequencing), Canu version 1.8 \[[@B35-antibiotics-09-00261]\] (MinION sequencing) and Unicycler version 0.4.8-beta \[[@B36-antibiotics-09-00261]\] (hybrid assemblies).

The statistics showing the parameters of the isolate sequencing and assembly are shown in [Table 4](#antibiotics-09-00261-t004){ref-type="table"}. All assemblies were uploaded to NCBI Genbank under the project number PRJNA580263.

4.2. Ethical Statement {#sec4dot2-antibiotics-09-00261}
----------------------

Ethical approval was not required as human samples were routinely collected and patients' data remained anonymous. The planning conduct and reporting of the study was in line with the Declaration of Helsinki, as revised in 2013.

4.3. Determination of Antibiotic Susceptibility {#sec4dot3-antibiotics-09-00261}
-----------------------------------------------

All isolates were identified down to a species level by time-of-flight mass spectrometry (MALDI-TOF MS) using the VITEC MS system (bioMerieux, Marcy-l'Étoile, France). The susceptibility was determined by the disc diffusion method using the Mueller--Hinton medium (bioMerieux, Marcy-l'Étoile, France) and disks with antibiotics (BioRad, Marnes-la-Coquette, France), and by the boundary concentration method on a VITEK2Compact30 analyzer (bioMerieux, Marcy-l'Étoile, France). The isolates were tested for susceptibility/resistance to the following drugs: amikacin, ampicillin, aztreonam, cefepime, cefotaxime, ceftazidime, ceftriaxone, ciprofloxacin, colistin, doripenem, gentamicin and tigecycline. Imipenem and meropenem were also tested, but yielded the same results as doripenem in terms of resistance/susceptibility, so they are not included in the output results. The panel of antimicrobial compounds included for testing in this study reflected those agents used for human therapy in the Russian Federation. To interpret the results obtained, we used the clinical guidelines "Determination of the susceptibility of microorganisms to antimicrobial drugs", version 2015-02 (<http://www.antibiotic.ru/minzdrav/files/docs/clrec-dsma2015.pdf>) which are based on EUCAST 2015.

4.4. Data Processing {#sec4dot4-antibiotics-09-00261}
--------------------

The assembled genomes were processed using a custom software pipeline including a set of scripts for the seamless integration of various available software tools. The main goal of the investigations was to determine the antibiotic resistance in silico, including both of the known acquired resistance genes and mutations facilitating the development of such a resistance. The parameters useful for epidemiological surveillance and investigating the presence of virulence factors were also studied.

The first step of the pipeline includes running BLAST on the "nt" database from NCBI locally to verify that the genomic sequence really belongs to the organism of interest. Then, multilocus sequence typing (MLST) \[[@B37-antibiotics-09-00261]\] was performed. After that, ResFinder \[[@B38-antibiotics-09-00261]\] was called to check for the presence of known antibiotic-resistant genes in the genomic sequence. Next, the steps included searching for known virulence genes with VirulenceFinder \[[@B39-antibiotics-09-00261]\] and detecting the plasmids in the input sequence using PlasmidFinder \[[@B40-antibiotics-09-00261]\]. In addition, it was reported that some infection control strategies involve targeting the *Klebsiella* surface polysaccharides \[[@B16-antibiotics-09-00261]\], which are engaged in the virulence mechanisms. Therefore, we also used Kaptive \[[@B16-antibiotics-09-00261]\] to search for the K- and O-loci of *K. pneumoniae,* which allow for defining the capsule synthesis type and lipopolysaccharide serotype, respectively, thus narrowing the isolate classification. Finally, the results obtained by the programs mentioned above were summarized and presented in a concise tabular form.

To build the phylogenetic tree representing the relations between the isolates, Prokka \[[@B41-antibiotics-09-00261]\] was used for the gene annotation, Roary \[[@B42-antibiotics-09-00261]\] for obtaining the core genome and RAxML \[[@B43-antibiotics-09-00261]\] for building the maximum likelihood tree itself. The graphs representing the antibiotic resistance and virulence factor presence were built using the ggplot2 R package.

5. Conclusions {#sec5-antibiotics-09-00261}
==============

In conclusion, here we presented a general report containing various types of molecular-based typing, antibiotic resistance profiling, virulence factors and plasmid descriptions for 36 clinical *K. pneumoniae* isolates from Moscow, Russia, among which 32 isolates exhibited an MDR phenotype. Although WGS in general, and long-read sequencing in particular, allows getting some insights into the resistance transmission and spreading of pathogenic isolates across hospital departments, more research, which is currently underway, is needed to analyze the mechanisms of the resistance acquisition and virulence of these isolates.

We thank the team of the curators of the Institut Pasteur MLST system (Paris, France) for importing novel profiles and isolates at <http://bigsdb.pasteur.fr>.

The following are available online at <https://www.mdpi.com/2079-6382/9/5/261/s1>, Table S1. Virulence genes revealed in the whole genomes of the isolates.
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antibiotics-09-00261-t001_Table 1

###### 

Description and molecular typing (multilocus sequence typing (MLST) (ST), capsule synthesis (KL)-type and lipopolysaccharide serotype (O-type)) of the isolates used in the study.

  Sample id   Patient Code   Year Collected   Hospital Department   Site                       ST             KL-Type   O-Type
  ----------- -------------- ---------------- --------------------- -------------------------- -------------- --------- ---------
  **P-6**     A1             2017             ICU                   blood                      ST453          KL8       O2v2
  **P-26**    A2             2017             Surgery               traumatic discharge        ST377          KL102     O2v2
  **P-28**    A3             2017             ICU                   tracheal aspirate          ST377          KL102     O2v2
  **P-29**    A4             2017             ICU                   tracheal aspirate          ST147          KL10      O3/O3a
  **P-45**    A5             2017             Urology               Sputum                     **ST4060\***   KL30      O1v1
  **P-68**    A6             2017             Rehabilitation        Urine                      ST11           KL24      O2v1
  **P-69**    A7             2017             ICU                   Sputum                     ST29           KL30      O1v2
  **P-75**    A8             2017             ICU                   Blood                      ST395          KL108     O1v2
  **P-99**    A9             2017             ICU                   Urine                      ST147          KL64      O2v1
  **P-108**   A10            2017             Thoracic              tracheal aspirate          ST23           KL57      O2v2
  **P-115**   A11            2017             Rehabilitation        Urine                      ST35           KL22      O1v1
  **P-116**   A12            2017             ICU                   Blood                      ST11           KL27      O2v2
  **P-120**   A12            2017             ICU                   granulation tissue         ST11           KL27      O2v2
  **P-133**   A13            2017             Rehabilitation        Urine                      ST395          KL2       O1v1
  **P-134**   A14            2017             Hematology            Blood                      ST395          KL2       O1v1
  **P-137**   A15            2017             Gastroenterology      Urine                      ST395          KL2       O1v1
  **P-140**   A16            2017             Hematology            Blood                      ST23           KL57      O2v2
  **P-142**   A17            2017             ICU                   Faeces                     ST147          KL64      O2v1
  **P-152**   A18            2017             Urology               Urine                      ST377          KL102     O2v2
  **P-154**   A19            2017             ICU                   Blood                      ST11           KL24      O2v1
  **P-160**   A20            2017             Hematology            nasal swab                 ST307          KL102     O2v2
  **P-176**   A21            2017             ICU                   Faeces                     ST11           KL24      O2v1
  **P-183**   A22            2017             Cardiology            Urine                      ST11           KL23      O2v2
  **P-185**   A23            2017             Rehabilitation        Urine                      ST147          KL64      O2v1
  **P-187**   A24            2017             Surgery               traumatic discharge        ST395          KL2       O1v1
  **P-190**   A25            2017             Therapy               Sputum                     ST54           KL14      O3b
  **P-197**   A26            2018             ICU                   Gall bladder               ST26           KL10      O1v2
  **P-200**   A27            2018             Cardiology            Sputum                     ST336          KL25      O5
  **P-212**   A28            2018             ICU                   bronchoalveolar lavage     **ST4061**     KL105     O4
  **P-223**   A29            2018             ICU                   traumatic discharge        ST395          KL108     O1/O2v2
  **P-226**   A30            2018             Surgery               Blood                      ST307          KL102     O2v2
  **P-234**   A31            2018             ICU                   abdominal cavity apostem   ST395          KL39      O1v1
  **P-237**   A32            2018             ICU                   Blood                      ST15           KL112     O1v1
  **P-250**   A33            2018             Hematology            Blood                      ST20           KL111     O3b
  **P-253**   A34            2018             ICU                   Urine                      ST15           KL112     O1v1
  **P-259**   A28            2018             ICU                   Faeces                     **ST4061**     KL105     O4

\*novel sequence types found by us are shown in bold; the isolates sequenced on MinION are filled with a gray color; ICU--intensive care unit.

antibiotics-09-00261-t002_Table 2

###### 

Allelic profiles for novel *K. pneumoniae* sequence types ST4060 and ST4061.

  *gapA*   *infB*   *mdh*   *pgi*   *phoE*   *rpoB*   *tonB*   ST
  -------- -------- ------- ------- -------- -------- -------- ------
  2        4        2       1       26       1        2        4060
  4        1        1       26      66       4        472      4061

antibiotics-09-00261-t003_Table 3

###### 

Plasmid sequences found in the isolates.

  Sample id\\Plasmid Type   Col          Inc (Other)                                         IncR
  ------------------------- ------------ --------------------------------------------------- ------
  P-6                       Col(BS512)   IncFIB(K)\_Kpn3                                     \-
  P-26                      ColRNAI      IncHI1B_pNDM-MAR, IncL/M(pOXA-48)\_pOXA-48, IncQ1   \-
  P-28                      ColRNAI      IncHI1B_pNDM-MAR, IncL/M(pOXA-48)\_pOXA-48          \-
  P-29                      Col(BS512)   \-                                                  IncR
  P-45                      \-           \-                                                  \-
  P-68                      Col(BS512)   IncFIB(K)\_Kpn3, IncFII(K)                          IncR
  P-69                      \-           \-                                                  \-
  P-75                      Col(BS512)   IncFII                                              IncR
  P-99                      \-           IncFIB(pQil)\_pQil, IncHI1B_pNDM-MAR                \-
  P-108                     ColRNAI      IncFII, IncQ1                                       \-
  P-115                     \-           \-                                                  \-
  P-116                     \-           IncL/M                                              IncR
  P-120                     \-           IncL/M                                              IncR
  P-133                     \-           \-                                                  IncR
  P-134                     \-           IncL/M(pOXA-48)\_pOXA-48, IncX4                     IncR
  P-137                     \-           IncFIB(Mar)\_pNDM-Mar                               IncR
  P-140                     ColRNAI      IncL/M(pOXA-48)\_pOXA-48                            \-
  P-142                     \-           IncFIB(pQil)\_pQil, IncHI1B_pNDM-MAR                \-
  P-152                     ColRNAI      IncHI1B_pNDM-MAR, IncL/M                            \-
  P-154                     Col(BS512)   \-                                                  IncR
  P-160                     \-           \-                                                  \-
  P-176                     Col(BS512)   \-                                                  IncR
  P-183                     ColRNAI      IncA/C2, IncFIB(K)\_Kpn3, IncFII(K)                 \-
  P-185                     Col440II     IncFII(pKPX1)\_AP012055, IncL/M(pOXA-48)\_pOXA-48   IncR
  P-187                     \-           IncL/M                                              IncR
  P-190                     \-           \-                                                  \-
  P-197                     \-           \-                                                  IncR
  P-200                     \-           IncHI1B_pNDM-MAR                                    \-
  P-212                     \-           IncFII(K)                                           \-
  P-223                     \-           IncL/M(pOXA-48)\_pOXA-48                            IncR
  P-226                     \-           IncL/M(pOXA-48)\_pOXA-48                            \-
  P-234                     Col(BS512)   IncL/M(pOXA-48)\_pOXA-48                            IncR
  P-237                     Col(BS512)   IncFIB(pQil)\_pQil                                  \-
  P-250                     \-           \-                                                  \-
  P-253                     Col(BS512)   IncFIB(pQil)\_pQil                                  \-
  P-259                     \-           IncFII(K)                                           \-

antibiotics-09-00261-t004_Table 4

###### 

Sequencing and assembly characteristics for the 36 isolates studied.

  Id          Num_Reads   Num_Contigs   Coverage   N50
  ----------- ----------- ------------- ---------- --------
  **P-6**     9132788     347           120        141817
  **P-26**    7655908     94            87         225016
  **P-28**    11221516    91            124        249107
  **P-29**    8340716     121           83         319263
  **P-45**    11426428    52            192        316824
  **P-68**    14543708    67            183        261596
  **P-69**    15629276    57            210        407523
  **P-75**    2399707     164           64         145594
  **P-99**    9478824     101           105        206727
  **P-108**   7790180     82            133        307643
  **P-115**   4387439     102           120        174171
  **P-116**   4865862     114           136        159297
  **P-120**   4977489     155           138        157758
  **P-133**   6947364     78            125        216945
  **P-134**   6276120     126           101        160646
  **P-137**   7006012     103           101        195276
  **P-140**   8749020     85            144        200903
  **P-142**   9410400     89            162        277906
  **P-152**   577309      132           28         164261
  **P-154**   496548      92            26         163095
  **P-160**   567724      134           28         203932
  **P-176**   17679448    78            200        262658
  **P-183**   2441972     128           50         179904
  **P-185**   2799220     92            53         230734
  **P-187**   3693052     139           75         134707
  **P-190**   2891576     157           59         177583
  **P-197**   18464812    156           214        145689
  **P-200**   22009116    114           248        264170
  **P-212**   7357356     71            155        353295
  **P-223**   11821000    114           222        260983
  **P-226**   9195800     107           175        280687
  **P-234**   9399924     95            155        207047
  **P-237**   4088672     82            87         209627
  **P-250**   18130280    97            209        345165
  **P-253**   16252888    77            173        196726
  **P-259**   5654368     108           64         241983

The isolates marked in gray color were also sequenced on MinION.

[^1]: The authors contributed equally.
